All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia

1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy, an all-oral regimen of decitabine–cedazuridine plus venetoclax was well tolerated without higher-grade toxic effects. 2. In the phase 2b segment, a complete response was achieved in nearly half of patients who received the intervention. Evidence […] The post…